• Home
  • Research
  • Institutional Research

Funded Research

Article Index

Pathology

“HPV”Ahead: Role of human papillomavirus infection and other co-factors in the etiology of head and neck cancer in Europe and India

Funding Agency: IARC
Duration: 2015-16
Principal Investigator: Gangane NM
Ethics Approval:

---------------------------------------------------------------------------------------------------------------------------------------

Expression of ER,PR, HER2/neu, Ki67 and p53 markers in endometrial carcinoma: Clinicopathological implications and prognostic value

Funding Agency: MUHS Nashik
Duration: 2015-16
Principal Investigator: Shivkumar VB, Atram M, Gangane N
Ethics Approval:

---------------------------------------------------------------------------------------------------------------------------------------

Prognostic value of expression of cytokeratin 5/6, EGFR,E-cadherin and p53 in triple negative breast cancers in central India

Funding Agency: MUHS Nashik
Duration: 2015-16
Principal Investigator: Anshu, Waghmare S, Gangane N
Ethics Approval:

---------------------------------------------------------------------------------------------------------------------------------------

Population Based Cancer Registry of Wardha District

Funding Agency: ICMR
Duration of Study: 2010 onwards
Principal Investigator: Dr Nitin Gangane
Ethics Approval: Obtained from Institutional Ethics Committee, MGIMS

------------------------------------------------------------------------------------------------------------------------------------

Prognostic value of expression of cytokeratin 5/6, EGFR, e-cadherin and p53 in triple negative breast cancers in central India

Funding Agency: MUHS
Pricipal Investigator: Dr Anshu, Dr Nitin Gangane
Duration of Study: 2014 onwards

Ethics Approval: Obtained from Institutional Ethics Committee, MGIMS (MGIMS/ IEC/PATH/56/2014; dated 06/09/2014)

Breast cancer is the one of the commonest malignancies in Indian women. It is a complex disease entity with different biological characteristics and clinical behavior. Although the incidence of breast cancer is very high, the overall mortality due to breast cancer has decreased, attributed partly to the early application of various therapies. To reduce mortality from breast cancer further, there is a desire to examine and characterize tumours of poor prognosis, predict their biology, ensure appropriate therapy and improve patient outcome. Many clinical and pathological features have been defined to predict treatment response and outcome in breast cancer. Classically these include: age, tumor size, axillary node involvement, angio-lymphatic invasion, histological grade, estrogen receptor status (ER), progesterone receptor status (PR) and HER-2/neu expression.

Tumours which do not express ER, PR and HER-2/ neu are called triple negative breast cancer (TNBC). Emerging data on the clinical implications of infiltrating duct carcinoma (IDC) with the triple-negative phenotype indicates an aggressive course of the disease and poor clinical outcome. Despite the widespread acknowledgment of the poor clinical outcome, the prognostic value of specific morphological and biological features of these tumors continues to raise a substantial degree of uncertainty and controversy. Availability of additional tumor markers might allow identification of patients at higher risk.

It should be emphasized that triple negative breast cancers currently include a heterogeneous group of tumors, and that the identification of tumor subtypes amenable to targeted treatments still represents a research priority. There is currently no specific targeted treatment for patients with TNBC, due to the lack of data on which to base treatment selection. An easily obtainable immunohistochemical profile is the most suitable approach for the proper identification of triple-negative breast cancers.

The aim of this study is to identify further immunohistochemical markers which will help in identifying tumours with more aggressive behaviour and poor prognosis. The specific objective of this study is to determine expression of epidermal growth factor receptor (EGFR), e-cadherin, CK 5/6, and p53 in triple negative breast cancers (TNBC). As part of this study, the investigators will conduct immunohistochemical studies on archival paraffin sections of breast carcinoma. They will compare expression of these markers in cases of triple negative breast cancer with cases that express hormonal receptors. This will provide further insights into the behavior of this group of cancers and the usefulness of these markers to predict prognosis.

------------------------------------------------------------------------------------------------------------------------------------

Copyright © 1969 - 2019 Mahatma Gandhi Institute of Medical Sciences

website security